Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 12:30:105552.
doi: 10.1016/j.dib.2020.105552. eCollection 2020 Jun.

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

D Zanon  1 , A Manca  2 , A De Nicolò  2 , A D'Avolio  2 , U M Musazzi  3 , F Cilurzo  3 , N Maximova  1 , C Tomasello  4 , P Minghetti  3
Affiliations

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

D Zanon et al. Data Brief. .

Abstract

The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed combination, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Unfortunately, for most of them, the drug products available on the market are not designed to be administered by a nasogastric tube to inpatients of intensive care units. Therefore, their manipulation, even if it can strongly affect the product quality, is necessary for the preparation of suspension to meet patients' need. In this situation, it is urgent to provide data and guidance to support hospital pharmacists and clinicians in their activity. The data in this article indicate that darunavir/cobicistat suspensions compounded by pharmacists using as active ingredient a commercially available tablet can be stable at least for one week.

Keywords: Cobicistat; Covid-19; Darunavir; Medicament manipulation; Nasogastric tube.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

References

    1. WHO, Q&a on COVID-19, HIV Aantiretrovirals. https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-hiv-and-antiret...(accessed: 21 March 2020).
    1. Council of Europe, Resolution CM/Res(2016)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. https://www.edqm.eu/sites/default/files/resolution_cm_res_2016_1_quality...(accessed: 20 December 2019). - PMC - PubMed
    1. Minghetti P., Pantano D., Gennari C.G.M., Casiraghi A. Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe. Health Policy (New York) 2014;117:328–333. - PubMed
    1. EMA, RezolstaⓇ. https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta(accessed: 21 March 2020).
    1. D'Avolio A., Baietto L., Siccardi M., Sciandra M., Simiele M., Oddone V., Bonora S., Di Perri G. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008;30:662–669. - PubMed